Thomas Sejersen
Overview
Explore the profile of Thomas Sejersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
2044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Udo C, Lovgren M, Sejersen T, Kreicbergs U
J Pediatr Rehabil Med
. 2025 Feb;
17(3):299-306.
PMID: 39973581
Purpose: This study aimed to explore how parents and grandparents of children with spinal muscular atrophy (SMA) perceived how the COVID-19 pandemic affected their access to medication and physiotherapy. Further,...
2.
Holzwarth D, Calaminus G, Friese J, Sejersen T, Buning H, John-Neek P, et al.
Mol Ther
. 2025 Feb;
PMID: 39955617
Spinal muscular atrophy (SMA) is a severe neuromuscular disease, leading to progressive muscle weakness and potentially early mortality if untreated. Onasemnogene abeparvovec is a recombinant adeno-associated virus serotype 9 (rAAV9)-based...
3.
Castro D, Sejersen T, Bello L, Buccella F, Cairns A, Carranza-Del Rio J, et al.
Eur J Paediatr Neurol
. 2025 Feb;
54:130-139.
PMID: 39892019
Background: Duchenne muscular dystrophy (DMD) is a rare neuromuscular disorder characterized by a progressive decline in muscle function, leading to loss of ambulation, respiratory and cardiac failure, and ultimately death....
4.
Maya-Gonzalez C, Tettamanti G, Taylan F, Nordenvall A, Sejersen T, Nordgren A
Neurology
. 2024 Sep;
103(8):e209883.
PMID: 39298705
Background And Objectives: Muscular dystrophies and myotonic disorders are genetic disorders characterized by progressive skeletal muscle degeneration and weakness. Epidemiologic studies have found an increased cancer risk in myotonic dystrophy,...
5.
Schroth M, Deans J, Arya K, Castro D, De Vivo D, Gibbons M, et al.
Neurol Clin Pract
. 2024 Jun;
14(4):e200310.
PMID: 38915908
Background And Objectives: Spinal muscular atrophy (SMA) is an autosomal recessive progressive neurodegenerative primary motor neuron disorder caused by biallelic variants of the survival motor neuron 1 () gene. The...
6.
Cui M, Jannig P, Halladjian M, Figueiredo V, Wen Y, Vechetti I, et al.
Am J Physiol Cell Physiol
. 2024 Jun;
327(3):C516-C524.
PMID: 38912733
In cell biology, ribosomal RNA (rRNA) 2'-methyl (2'--Me) is the most prevalent posttranscriptional chemical modification contributing to ribosome heterogeneity. The modification involves a family of small nucleolar RNAs (snoRNAs) and...
7.
Kirschner J, Bernert G, Butoianu N, Waele L, Fattal-Valevski A, Haberlova J, et al.
Eur J Paediatr Neurol
. 2024 Jun;
51:73-78.
PMID: 38878702
Spinal muscular atrophy (SMA) is one of the most common genetic diseases and was, until recently, a leading genetic cause of infant mortality. Three disease-modifying treatments have dramatically changed the...
8.
Sejersen T, Graham S, Ekstrom A, Kroksmark A, Kwiatkowska M, Ganz M, et al.
Eur J Health Econ
. 2024 Apr;
26(1):35-48.
PMID: 38642267
Background: Spinal muscular atrophy (SMA) is a rare, progressive, neuromuscular disorder. Recent advances in treatment require an updated assessment of burden to inform reimbursement decisions. Objectives: To quantify healthcare resource...
9.
10.
Golli T, Jurikova L, Sejersen T, Dixon C
BMC Neurol
. 2024 Feb;
24(1):73.
PMID: 38383326
Background: This paper details the results of an evaluation of the level of consensus amongst clinicians on the use of ataluren in both ambulatory and non-ambulatory patients with nonsense mutation...